Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
ARPC1B binds WASP to control actin polymerization and curtail tonic signaling in B cells
Gabriella Leung, … , Aleixo M. Muise, Spencer A. Freeman
Gabriella Leung, … , Aleixo M. Muise, Spencer A. Freeman
Published October 21, 2021
Citation Information: JCI Insight. 2021;6(23):e149376. https://doi.org/10.1172/jci.insight.149376.
View: Text | PDF
Research Article Cell biology Immunology

ARPC1B binds WASP to control actin polymerization and curtail tonic signaling in B cells

  • Text
  • PDF
Abstract

Immune cells exhibit low-level, constitutive signaling at rest (tonic signaling). Such tonic signals are required for fundamental processes, including the survival of B lymphocytes, but when they are elevated by genetic or environmental causes, they can lead to autoimmunity. Events that control ongoing signal transduction are, therefore, tightly regulated by submembrane cytoskeletal polymers like F-actin. The actin-binding proteins that underpin the process, however, are poorly described. By investigating patients with ARPC1B deficiency, we report that ARPC1B-containing ARP2/3 complexes are stimulated by Wiskott Aldrich Syndrome protein (WASP) to nucleate the branched actin networks that control tonic signaling from the B cell receptor (BCR). Despite an upregulation of ARPC1A, ARPC1B-deficient cells were not capable of WASP-mediated nucleation by ARP2/3, and this caused the loss of WASP-dependent structures, including podosomes in macrophages and lamellipodia in B cells. In the B cell compartment, ARPC1B deficiency also led to weakening of the cortical F-actin cytoskeleton that normally curtails the diffusion of BCRs and ultimately resulted in increased tonic lipid signaling, oscillatory calcium release from the endoplasmic reticulum (ER), and phosphorylated Akt. These events contributed to skewing the threshold for B cell activation in response to microbial-associated molecular patterns (MAMPs). Thus, ARPC1B is critical for ARP2/3 complexes to control steady-state signaling of immune cells.

Authors

Gabriella Leung, Yuhuan Zhou, Philip Ostrowski, Sivakami Mylvaganam, Parastoo Boroumand, Daniel J. Mulder, Conghui Guo, Aleixo M. Muise, Spencer A. Freeman

×

Figure 5

ARPC1B is critical for ARP2/3-dependent podosome formation and function.

Options: View larger image (or click on image) Download as PowerPoint
ARPC1B is critical for ARP2/3-dependent podosome formation and function....
(A) Primary human monocyte–derived macrophages (hMDM) fixed and stained for F-actin, Vinculin, and ARPC1B on cover glass. (B) hMDM treated with CK-689 (control) or the ARP2/3 inhibitor CK-666 stained for ARPC1B and F-actin. (C) Healthy control and patient MDM fixed and stained as in A for Talin, HS-1, and Vinculin. (D) The percentage of cells that form podosomes imaged as in A and quantified for > 25 cells; n > 2. Data are shown as mean ± SD. (E) Representative Western blot for ARPC1B in control and silenced primary macrophages. (F) The number of podosomes per cell in control siRNA versus ARPC1B siRNA–treated hMDM. Data are shown as mean ± SD. Scale bars: 10 μm. *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts